Elevated ERK1/2 activity (phosphorylation), a major effector of the Ras/MAPK pathway, has been observed in 50% of primary breast tumors as compared to adjacent normal tissue [8], and ERK phosphorylation has also been shown to be elevated in breast tumor cells capable of metastasis [8, 9]. The gene discussed is MAPK3; the disease is breast neoplasm.